First, the study designs of the 6 included trials differed, including in their use of placebo, choice of P2Y12 inhibitor, use of oral anticoagulation, proportion of acute coronary syndrome, and timing of randomization. The gene discussed is P2RY12; the disease is acute coronary syndrome.